Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2022

open access

Vol 94, No 9 (2023)
Guidelines / Expert consensus
Published online: 2022-09-22
View PDF Download PDF file View HTML
Get Citation

Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland

Andrzej Nowakowski12, Robert Jach3, Leszek Szenborn4, Mariusz Bidzinski56, Teresa Jackowska7, Jan Kotarski8, Agnieszka Mastalerz-Migas9, Aneta Nitsch-Osuch10, Jaroslaw Pinkas11, Wlodzimierz Sawicki12, Piotr Sieroszewski13, Maciej Stukan1415, Jacek Wysocki1617
DOI: 10.5603/GP.a2022.0101
·
Pubmed: 36134760
·
Ginekol Pol 2023;94(9):759-767.
Affiliations
  1. Cervical Cancer Prevention Clinic, Central Coordinating Centre for Cervical Cancer Screening Program, Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, Poland
  2. Obstetrics and Gynaecology Ward, District Specialist Hospital, Siedlce, Poland
  3. Department of Endocrine Gynaecology, Collegium Medicum of the Jagiellonian University, Cracow, Poland
  4. Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland, Wroclaw, Poland
  5. Department of Oncological Gynaecology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  6. Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland
  7. Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland
  8. Medical University in Lublin, Lublin, Poland
  9. Chair and Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland
  10. Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland
  11. School of Public Health, Medical Centre of Postgraduate Education, Warsaw, Poland
  12. Chair and Department of Obstetrics, Women’s Diseases and Oncological Gynaecology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland
  13. 1st Department of Gynaecology and Obstetrics, Medical University of Lodz, Poland, Poland
  14. Department of Gynaecological Oncology, Pomeranian Hospitals, Gdynia, Poland
  15. Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland
  16. Observation and Infectious Diseases Department of the Specialist Mother and Child Healthcare Group in Poznan, Poland, Poland
  17. Chair and Department of Health Prophylaxis, Medical University of Poznan, Poland

open access

Vol 94, No 9 (2023)
RECOMMENDATIONS
Published online: 2022-09-22

Abstract

Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, penile cancers, some head and neck cancers and genital warts (condylomas). The fraction HPV-related cancers range from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out on the pocket or in free-of-charge, local-governmental prevention programs, but the vaccination coverage of the target population does not exceed 10%. From November 2021, one of the vaccines is available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teen population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes reaches almost 100%, provided that full post-vaccination immunity is obtained before the contact with the virus. Girls aged 11-13 are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Program (PIP) for all adolescents should be pursued. Persons over the age of 13 may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.

Abstract

Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, penile cancers, some head and neck cancers and genital warts (condylomas). The fraction HPV-related cancers range from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out on the pocket or in free-of-charge, local-governmental prevention programs, but the vaccination coverage of the target population does not exceed 10%. From November 2021, one of the vaccines is available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teen population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes reaches almost 100%, provided that full post-vaccination immunity is obtained before the contact with the virus. Girls aged 11-13 are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Program (PIP) for all adolescents should be pursued. Persons over the age of 13 may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

human papillomavirus; prophylactic vaccination; cervical cancer

About this article
Title

Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland

Journal

Ginekologia Polska

Issue

Vol 94, No 9 (2023)

Article type

Guidelines / Expert consensus

Pages

759-767

Published online

2022-09-22

Page views

1329

Article views/downloads

523

DOI

10.5603/GP.a2022.0101

Pubmed

36134760

Bibliographic record

Ginekol Pol 2023;94(9):759-767.

Keywords

human papillomavirus
prophylactic vaccination
cervical cancer

Authors

Andrzej Nowakowski
Robert Jach
Leszek Szenborn
Mariusz Bidzinski
Teresa Jackowska
Jan Kotarski
Agnieszka Mastalerz-Migas
Aneta Nitsch-Osuch
Jaroslaw Pinkas
Wlodzimierz Sawicki
Piotr Sieroszewski
Maciej Stukan
Jacek Wysocki

References (59)
  1. https://hpvcentre.net/ (20.10.2021).
  2. https://www.mp.pl/szczepienia/artykuly/przegladowe/186457,co-wiadomo-o-populacyjnych-efektach-szczepien-przeciwko-hpv (20.10.2021).
  3. de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141(4): 664–670.
    CrossRefPubMed
  4. Robenek M, Olejek A, Witek L, et al. Presence of human papilloma virus in Caucasian women living in the central Europe diagnosed with vulvar intraepithelial neoplasia. Ginekol Pol. 2020; 91(4): 181–184.
    CrossRefPubMed
  5. de Sanjose S, Quint WGv, Alemany L, et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11): 1048–1056.
    CrossRefPubMed
  6. Nowakowski A, de Souza SC, Jach R, et al. HPV-type distribution and reproducibility of histological diagnosis in cervical neoplasia in Poland. Pathol Oncol Res. 2015; 21(3): 703–711.
    CrossRefPubMed
  7. https://gco.iarc.fr/causes/infections/tools-pie?mode=2&sex=0&population=who&continent=0&country=0&population_group=0&cancer=0&key=attr_cases&lock_scale=0&pie_mode=1&nb_results=5, accessed on 20th October 2021.
  8. World Health Organization. Weekly Epidemiological Record. 2017; 92(19): 241–268.
  9. Stanley M. HPV vaccines: alternative dosage schedules. Expert Rev Vaccines. 2019; 18(12): 1309–1316.
    CrossRefPubMed
  10. Drolet M, Bénard É, Pérez N, et al. HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; 394(10197): 497–509.
    CrossRefPubMed
  11. Gidengil C, Goetz MB, Newberry S, et al. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine. 2021; 39(28): 3696–3716.
    CrossRefPubMed
  12. Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine. 2017; 35(13): 1729–1732.
    CrossRefPubMed
  13. Hviid A, Thorsen NM, Valentiner-Branth P, et al. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. BMJ. 2020; 370: m2930.
    CrossRefPubMed
  14. Barboi A, Gibbons CH, Axelrod F, et al. American Autonomic Society, American Autonomic Society. Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clin Auton Res. 2020; 30(1): 13–18.
    CrossRefPubMed
  15. Gøtzsche PC, Jørgensen KJ. EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines. BMJ Evid Based Med. 2022; 27(1): 7–10.
    CrossRefPubMed
  16. Tatang C, Arredondo Bisonó T, Bergamasco A, et al. Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. Drugs Real World Outcomes. 2022; 9(1): 79–90.
    CrossRefPubMed
  17. Bonaldo G, Vaccheri A, D'Annibali O, et al. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. Br J Clin Pharmacol. 2019; 85(3): 634–643.
    CrossRefPubMed
  18. Vichnin M, Bonanni P, Klein NP, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015; 34(9): 983–991.
    CrossRefPubMed
  19. Joura EA, Giuliano AR, Iversen OE, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8): 711–723.
    CrossRefPubMed
  20. Goss MA, Lievano F, Buchanan KM, et al. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine. 2015; 33(29): 3422–3428.
    CrossRefPubMed
  21. Scheller NM, Pasternak B, Mølgaard-Nielsen D, et al. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes. N Engl J Med. 2017; 376(13): 1223–1233.
    CrossRefPubMed
  22. Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J. 2014; 33(12): 1255–1261.
    CrossRefPubMed
  23. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009; 2(10): 868–878.
    CrossRefPubMed
  24. Lehtinen M, Paavonen J, Wheeler C, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1): 89–99.
    CrossRef
  25. Hildesheim A, Wacholder S, Catteau G, et al. CVT Group. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014; 32(39): 5087–5097.
    CrossRefPubMed
  26. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364(5): 401–411.
    CrossRefPubMed
  27. Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020; 10: 100203.
    CrossRefPubMed
  28. Kjaer SK, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020; 23: 100401.
    CrossRefPubMed
  29. Lehtinen M, Apter D, Eriksson T, et al. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trial. Int J Cancer. 2020; 147(1): 170–174.
    CrossRefPubMed
  30. Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016; 1(1): e8–ee17.
    CrossRefPubMed
  31. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021; 398(10316): 2084–2092.
    CrossRefPubMed
  32. Lei J, Ploner A, Elfström K, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020; 383(14): 1340–1348.
    CrossRef
  33. Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst. 2021; 113(10): 1329–1335.
    CrossRefPubMed
  34. Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017. Vaccine. 2022; 40(2): 316–324.
    CrossRefPubMed
  35. Yuill S, Egger S, Smith M, et al. Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. J Infect Dis. 2020; 222(3): 499–508.
    CrossRefPubMed
  36. Dehlendorff C, Baandrup L, Kjaer SK. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst. 2021; 113(7): 869–874.
    CrossRefPubMed
  37. Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2018; 36(3): 262–267.
    CrossRefPubMed
  38. Denny LA, Franceschi S, de Sanjosé S, et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012; 30 Suppl 5: F168–F174.
    CrossRefPubMed
  39. Tanweer MS, Aljurf M, Savani BN, et al. Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives. Clin Hematol Int. 2019; 1(3): 142–153.
    CrossRefPubMed
  40. Wielgos AA, Pietrzak B. Human papilloma virus-related premalignant and malignant lesions of the cervix and anogenital tract in immunocompromised women. Ginekol Pol. 2020; 91(1): 32–37.
    CrossRefPubMed
  41. Gómez de la Rosa AG, Quesada López-Fe A, Vilar Chesa M, et al. Efficacy of Human Papillomavirus Vaccination 4 Years After Conization for High-Grade Cervical Neoplasia. J Low Genit Tract Dis. 2021; 25(4): 287–290.
    CrossRefPubMed
  42. Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel). 2021; 9(5).
    CrossRefPubMed
  43. Sand FL, Frederiksen K, Kjaer SK, et al. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2020; 147(3): 641–647.
    CrossRefPubMed
  44. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. WHO, Geneva 2020.
  45. European Centre for Disease Prevention and Control. Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. European Centre for Disease Prevention and Control, Stockholm 2020.
  46. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019; 68(32): 698–702.
    CrossRefPubMed
  47. Uchwała nr 10 Rady Ministrów z dnia 4 lutego 2020 r. w sprawie przyjęcia programu wieloletniego pn. Narodowa Strategia Onkologiczna na lata 2020-2030, Dz.U. 2019 poz. 969.
  48. Rekomendacja nr 128/2021 z dnia 25 listopada 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie oceny leku Gardasil, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 6, 11, 16, 18] we wskazaniu: zapobieganie wystąpienia u osób w wieku od 9 lat: zmian przednowotworowych narządów płciowych (szyjki macicy, sromu i pochwy), zmian przednowotworowych odbytu, raka szyjki macicy oraz raka odbytu, związanych przyczynowo z zakażeniem pewnymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV); brodawek narządów płciowych (kłykcin kończystych) związanych przyczynowo z zakażeniem określonymi typami wirusa brodawczaka ludzkiego.
  49. Rekomendacja nr 54/2021 z dnia 18 maja 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie objęcia refundacją leku Cervarix, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 16 i 18] we wskazaniu: profilaktyka zmian przednowotworowych narządów płciowych i odbytu (szyjki macicy, sromu, pochwy i odbytu) oraz raka szyjki macicy i raka odbytu związanych przyczynowo z określonymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV) u osób od ukończenia 9. roku życia.
  50. Nowakowski A, Arbyn M, Turkot MH, et al. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev. 2020; 29(2): 157–164.
    CrossRefPubMed
  51. Bidziński M, Debski R, Kedzia W, et al. Stanowisko zespołu ekspertów Polskiego Towarzystwa Ginekologicznego na temat profilaktyki raka gruczołowego szyjki macicy. Ginekol Pol. 2008; 79(10): 710–714.
  52. Pediatria Polska. 85; 4(Lipiec-Sierpień 2010).
  53. Agencja Oceny Technologii Medycznych i Taryfikacji, Wydział Oceny Technologii Medycznych. Profilaktyka zakażeń wirusem brodawczaka ludzkiego (HPV) w ramach programów polityki zdrowotnej Warszawa. Raport w sprawie zalecanych technologii medycznych, działań przeprowadzanych w ramach programów polityki zdrowotnej oraz warunków realizacji tych programów polityki zdrowotnej – materiały dla Rady Przejrzystości AOTMiT. Warszawa, 2019. https://bipold.aotm.gov.pl/assets/files/ppz/2019/RPT/19.10.29_raport_zalec_techn_art_48aa_profilaktyka_hpv.pdf (20.10.2021).
  54. Wydział Zdrowia i Spraw Społecznych Urzędu Miejskiego Wrocławia. Wrocławski program profilaktyki zakażeń wirusem brodawczaka ludzkiego. https://hpv.um.wroc.pl/?p=561 (20.10.2021).
  55. Ludwikowska KM, Szenborn L, Krzyżanowska I, et al. Potrzeba, bezpieczeństwo oraz realizacja szczepień przeciwko HPV - perspektywa wrocławska. Klin Pediatr . 2018; 26(1): 26–30.
  56. Ludwikowska KM, Biela M, Szenborn L. HPV vaccine acceptance and hesitancy - lessons learned during 8 years of regional HPV prophylaxis program in Wroclaw, Poland. Eur J Cancer Prev. 2020; 29(4): 346–349.
    CrossRefPubMed
  57. Nguyen-Huu NH, Thilly N, Derrough T, et al. HPV Policy working group. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine. 2020; 38(6): 1315–1331.
    CrossRefPubMed
  58. Brown B, Gabra MI, Pellman H. Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice. Papillomavirus Res. 2017; 3: 42–45.
    CrossRefPubMed
  59. Facciolà A, Visalli G, Orlando A, et al. Vaccine hesitancy: An overview on parents' opinions about vaccination and possible reasons of vaccine refusal. J Public Health Res. 2019; 8(1): 1436.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl